Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells

Area of Science:

• Biotechnology
• Immunology
• Molecular Biology

Background:

• Antibody therapeutics are clinically successful, but their efficacy depends on high affinity and specificity.
• Current antibody discovery methods, like phage display, face limitations in protein expression and diversity.
• A robust eukaryotic display system is needed to overcome these limitations and improve antibody optimization.

Purpose of the Study:

• To develop a eukaryotic display technology for antibody discovery and optimization.
• To evaluate avian leukosis virus (ALV) as a platform for antibody display.
• To improve the binding affinity of antibodies using ALV display.

Main Methods:

• Utilized the replication and polypeptide display capabilities of avian leukosis virus (ALV).
• Employed ALV display as a eukaryotic alternative to traditional phage display.
• Optimized a model single-chain variable fragment (Fv) antibody using ALV display.

Main Results:

• Demonstrated ALV display as a functional eukaryotic display system.
• Achieved a >2,000-fold improvement in antibody binding affinity, from micromolar to picomolar levels.
• Showcased the potential for enhanced antibody diversity and proper processing within the eukaryotic system.

Conclusions:

• ALV display offers a robust eukaryotic platform for antibody discovery and optimization.
• This technology extends antibody display capabilities beyond microbial systems.
• ALV display facilitates the development of high-affinity, functional antibody candidates for therapeutic applications.